Bounteous, an AI services firm, today announced its acquisition of Cartesian, a specialist consulting firm focused on the ...

So, the natural question for Cartesian Therapeutics (NASDAQ:RNAC) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual ...

A look at the shareholders of Cartesian Growth Corporation (NASDAQ:GLBL) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies ...

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...

Factorial Inc. (“Factorial” or the “Company”), a leader in solid-state battery technology, and Cartesian Growth Corporation III (“Cartesian III”) (NASDAQ: CGCT) today announced that their joint ...

The last time I spoke about Cartesian Therapeutics (RNAC) it was in a Seeking Alpha article entitled "Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data." There, I wrote about ...

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Tuesday revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, lead cell therapy candidate, in participants with generalized ...

NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation (“Cartesian”) (NASDAQ: GLBL), a publicly traded special purpose acquisition company, today announced that it has received the required ...

Cartesian Therapeutics, Inc. (RNAC) came out with a quarterly loss of $1.46 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $0.68 per share a year ago.